A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors.
Wednesday, June 19, 2024
Dr. Minal Barve
View abstract via above link.
![ASCO 2024 Poster for Trial 20-13](https://marycrowley.org/wp-content/uploads/2024/06/poster-6.jpg)
ASCO Poster for Trial 20-13